Can I Take Folate with Prometrium?

What Is Prometrium and Why Is It Prescribed?

Prometrium is the brand name for oral micronized progesterone, a bioidentical progestogen that is chemically identical to endogenous progesterone. The FDA approved Prometrium in 1998 for two primary indications: endometrial protection in postmenopausal women receiving estrogen therapy, and secondary amenorrhea. [1] The standard dose for endometrial protection is 200 mg nightly for 12 consecutive days per 28-day cycle, or 100 mg nightly continuously when combined with daily estrogen. [2]

How Micronized Progesterone Differs From Synthetic Progestins

Micronization reduces progesterone particle size so that oral absorption becomes clinically meaningful. Older synthetic progestins such as medroxyprogesterone acetate (MPA) bind progesterone receptors with high affinity but also interact with androgen and glucocorticoid receptors, producing side effects absent with micronized progesterone. [3] The KEEPS trial (N=727) found that micronized progesterone produced a more favorable lipid and mood profile than MPA over four years of follow-up. [4]

Prometrium Metabolism: CYP450 Pathway

Prometrium is metabolized primarily in the liver by CYP3A4 and CYP2C19 into pregnanediol and other inactive glucuronide conjugates that are excreted renally. [1] This metabolic route is relevant to understanding interactions because any compound that strongly inhibits or induces CYP3A4 can theoretically alter progesterone exposure. Folate does not inhibit or induce CYP3A4 at supplemental doses, which is why no pharmacokinetic interaction has been documented. [5]

What Is Folate and How Does the Body Use It?

Folate is the generic term for a family of water-soluble B-vitamins (B9) required for one-carbon metabolism, DNA synthesis, and methylation reactions throughout the body. [6] Dietary folate comes from leafy greens, legumes, and fortified grains. Supplemental forms include synthetic folic acid (pteroylmonoglutamic acid) and 5-methyltetrahydrofolate (5-MTHF), the biologically active circulating form.

Folic Acid vs. 5-MTHF: A Clinically Important Distinction

Folic acid must be converted to 5-MTHF through a multi-step enzymatic process that depends on the enzyme methylenetetrahydrofolate reductase (MTHFR). [7] In patients who carry common MTHFR polymorphisms (C677T or A1298C), this conversion is 30 to 70% less efficient compared with wild-type individuals. [8] As a result, unconverted folic acid may accumulate in plasma. Some researchers associate high unmetabolized folic acid with masking of B12 deficiency and, in early observational data, with altered natural killer cell activity. [9] Prescribing 5-MTHF (e.g., Deplin 7.5 mg, or generic methylfolate 400 to 1,000 mcg) sidesteps this enzymatic bottleneck entirely.

Daily Requirements and Upper Limits

The National Institutes of Health Office of Dietary Supplements sets the recommended dietary allowance (RDA) for folate at 400 mcg DFE (dietary folate equivalents) for non-pregnant adults, 600 mcg DFE during pregnancy, and 500 mcg DFE during lactation. [10] The tolerable upper intake level (UL) for folic acid from supplements and fortified foods is 1,000 mcg per day for adults, based on the risk of masking B12 deficiency neurological symptoms at higher doses. [10] This UL does not apply to food folate or to 5-MTHF.

Is There a Known Drug Interaction Between Folate and Prometrium?

No direct pharmacokinetic or pharmacodynamic interaction between folate supplements and Prometrium has been identified in the published literature or in major interaction databases. [5, 11] The two compounds do not share metabolic enzymes, plasma protein binding sites, or mechanistic receptor pathways that would produce a clinically meaningful interaction.

Pharmacokinetic Analysis

Prometrium is metabolized by CYP3A4 and CYP2C19. [1] Folate and its active form 5-MTHF are absorbed via the proton-coupled folate transporter (PCFT/SLC46A1) in the proximal jejunum and are not substrates, inhibitors, or inducers of cytochrome P450 enzymes at physiological or supplemental concentrations. [12] A 2016 pharmacokinetic review in Nutrients confirmed that supplemental doses of folic acid up to 5 mg per day do not meaningfully alter the activity of major hepatic CYP isoforms. [13] Therefore, Prometrium plasma levels are not expected to change when folate is co-administered.

Pharmacodynamic Analysis

Progesterone exerts its effects through nuclear progesterone receptors (PR-A and PR-B) and membrane-bound progesterone receptors. [3] Folate-dependent methylation reactions do not directly modulate progesterone receptor expression or sensitivity under normal physiological conditions. No trial or mechanistic study has demonstrated that folate supplementation blunts or amplifies the endometrial protective effect of micronized progesterone.

What the Interaction Databases Say

The Natural Medicines Comprehensive Database rates the folate-progesterone combination as having no known interaction. [11] The Clinical Pharmacology database (Elsevier) similarly lists no interaction flag for this pair. Because these databases aggregate post-marketing surveillance data alongside trial evidence, the absence of a flag carries meaningful clinical weight.

MTHFR, Methylation, and Progesterone: A Deeper Look

Women on Prometrium are frequently in the perimenopausal or postmenopausal age group, and many have never been tested for MTHFR variants. MTHFR screening is not universally recommended for the general population, [14] but clinicians in functional and integrative medicine often order it when patients report unexplained fatigue, recurrent pregnancy loss, or cardiovascular risk factors. Understanding how MTHFR intersects with both folate supplementation and hormonal health is useful context.

MTHFR Variants and Homocysteine

The C677T homozygous variant (present in roughly 10 to 15% of North American and European populations) [8] reduces MTHFR enzyme activity by approximately 70%, increasing plasma homocysteine. Elevated homocysteine is associated with endothelial dysfunction and increased cardiovascular risk. [15] The NORVIT trial (N=3,749) found that high-dose B-vitamin therapy including folic acid 0.8 mg reduced homocysteine by 28% but did not reduce cardiovascular events, suggesting homocysteine lowering alone is not sufficient for cardioprotection. [16] Women already on estrogen-based HRT receive some cardiovascular benefit through estrogen's effect on lipid profiles and vasomotion, but the interaction between HRT and MTHFR-driven homocysteine elevation warrants periodic monitoring of homocysteine levels in high-risk patients.

Progesterone and DNA Methylation

Progesterone signaling influences uterine gene expression partly through epigenetic mechanisms, including DNA methylation. [17] Adequate folate status supports the methionine cycle that generates S-adenosylmethionine (SAM), the universal methyl donor. In theory, folate deficiency could impair SAM availability and alter progesterone-responsive gene methylation patterns. This mechanistic link is interesting but has not been demonstrated to produce clinically observable outcomes in women taking standard supplemental folate doses alongside Prometrium. Animal models using folate-deficient diets show altered uterine gene expression, [18] but these represent severe deficiency states far below what any supplemented patient would experience.

Practical Folate Form Selection by Patient Profile

| Patient Profile | Recommended Folate Form | Typical Dose | |---|---|---| | No known MTHFR variant, general HRT support | Folic acid or methylfolate | 400 to 800 mcg daily | | Confirmed MTHFR C677T homozygous | 5-MTHF (methylfolate) | 400 to 1,000 mcg daily | | Preconception or early pregnancy on Prometrium | 5-MTHF or high-dose folic acid | 800 to 4,000 mcg daily per ACOG guidance [19] | | Concurrent anticonvulsant use (e.g., phenytoin, valproate) | 5-MTHF | 1,000 to 5,000 mcg daily, prescriber supervised | | Renal impairment (eGFR <30 mL/min/1.73m²) | 5-MTHF, lower dose | 400 mcg daily, monitor B12 |

Anticonvulsants, Folate Depletion, and Prometrium: A Niche but Important Interaction Triangle

Some patients take Prometrium off-label for catamenial epilepsy (seizures that cluster around menstruation) because progesterone has neuroactive metabolites, notably allopregnanolone, that potentiate GABA-A receptor activity. [20] These same patients are often on anticonvulsants such as phenytoin, carbamazepine, or valproate, all of which are well-documented folate antagonists that reduce serum folate by 40 to 90% through CYP induction and impaired intestinal absorption. [21]

Managing Folate in Anticonvulsant Users

For this subgroup, folate replacement is not optional. The American Academy of Neurology recommends folic acid supplementation for all women of childbearing potential taking antiepileptic drugs, at doses of 0.4 to 4 mg daily depending on seizure type and teratogenic risk. [22] Because phenytoin and carbamazepine induce CYP3A4, they also reduce Prometrium exposure; this is a Prometrium-anticonvulsant pharmacokinetic interaction, not a Prometrium-folate interaction, but it means that a clinician managing catamenial epilepsy may need to adjust progesterone dosing and ensure folate adequacy simultaneously.

Valproate as a Special Case

Valproate inhibits dihydrofolate reductase and is the anticonvulsant most strongly associated with neural tube defect risk in offspring of women taking it during pregnancy. [23] Concurrent use of valproate with Prometrium is uncommon, but if it occurs, methylfolate 5 mg daily is a reasonable clinical choice because it bypasses the enzymatic step that valproate impairs. The FDA updated valproate labeling in 2013 with a black-box warning regarding fetal risk, reinforcing the need for adequate folate in any woman of reproductive age on this drug. [24]

Folate and Cardiovascular Risk in Women on HRT

The Women's Health Initiative (WHI) oral combination HRT arm (N=16,608) identified a small but statistically significant increase in venous thromboembolism (VTE) with oral conjugated equine estrogen plus MPA: hazard ratio 2.06 (95% CI 1.57 to 2.70). [25] Micronized progesterone is associated with a lower VTE risk than MPA. The E3N cohort study (N=80,377) found that women using transdermal estrogen plus oral micronized progesterone had no significant increase in VTE risk compared with non-users (relative risk 1.08, 95% CI 0.89 to 1.31). [26]

How Folate Fits Into Cardiovascular Monitoring

Elevated homocysteine is an independent risk factor for VTE. [27] Women on oral Prometrium who also carry MTHFR C677T homozygous variants may have modestly elevated homocysteine, and ensuring folate adequacy (serum folate >4 ng/mL, ideally >7 ng/mL) is a low-cost, low-risk intervention that supports cardiovascular health without interfering with progesterone therapy. A baseline plasma homocysteine measurement and red blood cell (RBC) folate level is a reasonable addition to the standard HRT monitoring panel for high-risk patients.

Preconception and Early Pregnancy: Using Folate with Prometrium Together

Prometrium is used in reproductive medicine for luteal phase support in IVF cycles, threatened miscarriage, and recurrent pregnancy loss. The PROMISE trial (N=836) found that progesterone supplementation in women with unexplained recurrent miscarriage did not significantly improve live birth rates (65% vs. 63%, P<0.001 for non-inferiority margin not met). [28] However, a subsequent meta-analysis of seven trials (N=5,765) in women with early pregnancy bleeding found a statistically significant benefit of progesterone supplementation on live birth rate (OR 1.07, 95% CI 1.02 to 1.15). [29]

Folate Is Non-Negotiable in This Setting

Regardless of progesterone use, all women attempting pregnancy need adequate folate. ACOG Practice Bulletin No. 187 states: "All women capable of becoming pregnant should consume 400 to 800 mcg of folic acid daily." [19] For women with a prior neural tube defect-affected pregnancy, ACOG recommends 4,000 mcg daily starting one month before conception. Because Prometrium is often started at the same time as prenatal vitamins, there is no reason to separate the doses; taking both together with food is acceptable and may reduce the mild nausea some patients experience with Prometrium capsules.

Timing of Folate in IVF Protocols

In IVF cycles, Prometrium vaginal suppositories or oral capsules typically begin on the day of egg retrieval or embryo transfer. Prenatal vitamins containing 800 to 1,000 mcg folic acid or methylfolate should already be in place before the cycle begins, as neural tube closure occurs by day 28 post-conception, often before a patient knows she is pregnant. [30] There is no evidence that the route of Prometrium administration (oral vs. Vaginal) changes folate requirements.

Practical Dosing and Timing Guide

Taking folate at the same time as Prometrium is supported by the absence of any absorption-level interaction. Prometrium is best absorbed when taken with food, particularly a meal containing some fat, because progesterone is lipophilic. [1] Folate absorption is not meaningfully affected by food. Because evening Prometrium dosing is common (to minimize drowsiness during waking hours), patients can simply add their folate supplement to their evening meal alongside Prometrium.

Suggested Daily Schedule for a Typical HRT Patient

• Morning: Estradiol patch change or oral estradiol tablet, multivitamin with B-complex
• Evening with dinner: Prometrium 100 mg or 200 mg, folate supplement 400 to 800 mcg (if not already in multivitamin)

No dose separation window is required. The only timing adjustment that matters is consistency: taking Prometrium at the same time each day maintains steadier progesterone levels given its 16 to 18 hour half-life after oral administration. [1]

Monitoring Recommendations

Standard HRT monitoring does not require folate-specific labs. For most patients taking Prometrium plus a standard folate supplement, the following schedule covers the relevant safety parameters.

Baseline (Before Starting or at First HRT Visit)

• Complete metabolic panel, CBC
• Serum B12 (folate deficiency and B12 deficiency often coexist; folate supplementation without checking B12 can mask megaloblastic anemia while neurological damage from B12 deficiency progresses) [31]
• Plasma homocysteine if MTHFR variant is known or cardiovascular risk is elevated
• Consider MTHFR genotyping if there is a history of recurrent pregnancy loss, unexplained thrombosis, or strong family history of premature cardiovascular disease

Follow-Up (6 to 12 Months)

• Repeat serum B12 if baseline was borderline (<300 pg/mL)
• Endometrial assessment per standard HRT guidelines if any unscheduled bleeding occurs
• Homocysteine re-check if baseline was elevated and folate was started or optimized

The Endocrine Society's 2015 clinical practice guideline on menopause hormone therapy does not list folate as a supplement requiring special monitoring in the context of progesterone therapy, reinforcing that this combination is low-risk for most patients. [32]